Penetration enhancing and irritation reducing systems

Details Penetration enhancing and irritation reducing systems Penetration enhancing and irritation reducing systems

2007-01-02

2007-01-02

Kim, Vickie (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S448000, C424S401000, C514S179000, C514S182000, C514S784000

Reexamination Certificate

active

10389715

ABSTRACT:
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

REFERENCES:
patent: 4537776 (1985-08-01), Cooper
patent: 4552872 (1985-11-01), Cooper et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4670255 (1987-06-01), Yoshizumi et al.
patent: 4737362 (1988-04-01), Yoshizumi et al.
patent: 4743588 (1988-05-01), Mirejovsky et al.
patent: 4863970 (1989-09-01), Patel et al.
patent: 5154922 (1992-10-01), Govil et al.
patent: 5391548 (1995-02-01), Francoeur et al.
patent: 5601839 (1997-02-01), Quan et al.
patent: 5607691 (1997-03-01), Hale et al.
patent: 5760096 (1998-06-01), Thornfeldt et al.
patent: 5780050 (1998-07-01), Jain et al.
patent: 5952000 (1999-09-01), Venkateshwaran et al.
patent: 6319913 (2001-11-01), Mak et al.
patent: 6579865 (2003-06-01), Mak et al.
patent: 2003/0175329 (2003-09-01), Azarnoff et al.
patent: 0267617 (1988-05-01), None
patent: 0331382 (1989-09-01), None
patent: 0371496 (1990-06-01), None
patent: 0416137 (1991-03-01), None
patent: 0416173 (1991-03-01), None
patent: 0811381 (1997-12-01), None
patent: WO 92/10231 (1992-06-01), None
patent: WO 9210231 (1992-06-01), None
patent: WO 9300058 (1993-01-01), None
patent: WO 9303751 (1993-03-01), None
patent: WO 93/25168 (1993-12-01), None
patent: WO 9529678 (1995-11-01), None
patent: WO 97/24148 (1997-07-01), None
patent: WO 99/47126 (1999-09-01), None
Bronaugh et al.; “Methods forIn VitroPercutaneous Absorption Studies VII: Use of Excised Human Skin”,J. Pharm.Sci.75(11):1094-1097.
Bronaugh et al.; “Methods forIn VitroPercutaneous Absorption Studies IV: the Flow-Through Diffusion Cell”,J. Pharm.Sci.74(1):64-67.
“Transdermal Drug Delivery” Ed. Jonathan Hadgraft et al.; Chapter 9, Marcel Dekker Inc., New York pp. 177-196.
Transdermal Delivery of Drugs, vol. II, pp. 86-87, CRC Press, Inc., Boca Raton, Florida. Editors Kydonieus and Berner, 1987.
Francoeur et al., Oleic Acid: Its Effects on Stratus Corneum in Relation to (Trans)Dermal Drug Delivery, Pharmaceutical Research, Nov. 6, 1990, pp. 621-627, vol. 7, Planum Publishing Corporation, 1990.
Bronaugh et al., Percutaneous Absorption, Mechanisms-Methodology-Drug Delivery, Mechanism of Percutaneous Absorption, pp. 28-30, Marcel Dekker, Inc, New York. Editors: Bronaugh and Maibach, 1985.
ANDRODERM® Testosterone Transdermal Patch Usage Directions (Ref. No. 200155-00/685692) © Theratech, Inc. (1996).
ANDRODERM® Testosterone Transdermal System Prescribing Information (Ref. No. 200122-02/585669) © SmithKline Beecham (1996).
ANDRODERM® entry in the Physician's Desk Reference®, pp. 3170-3172 (2000).
Barclay, L. et al., “High body mass index may increase risk of oral contraceptive failure,” Medscape Medical News from webMD, http://www.medscape.com/viewarticle/496784?src=mp (2005).
Cook C.B. et al., “Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system,”Diabetes Technol. Ther., vol. 6, No. 3; pp. 326-335 (2004).
Green B. and S.B. Duffull, “What is the best size descriptor to use for pharmacokinetic studies in the obese?”Br. J. Clin. Pharmacol., vol. 58, No. 2, pp. 119-133 (2004).
Key, T.J. et al., “Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women,”J. Nat'l Cancer Inst., vol. 95, No. 16, pp. 1218-1226 (2003).
Meikle, et al., “ANDRODERM®: A permeation enhanced non-scrotal testosterone transdermal system for the teatment of male hypogonadism,” Pharmacology, Biology and Clinical Application of Androgens, Bhasin et al. (Eds.) pp. 449-457 (1996).
Parker, S. and M. Armitage, “Experience with transdermal testosterone replacement therapy for hypogonadral men,”Clin. Endocrin., vol. 50, pp. 57-62 (1999).
Shouls, J. et al., “Contact allergy to testosterone in an androgen patch: control of symptoms by pre-application of topical corticosteroid,” Contact Dermatitis, vol. 45, pp. 124-125 (2001).
Steidle, C. et al., “AA2500 Testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function,”J. Clin. Endocrin.&Metabol., vol. 88, No. 6, pp. 2673-2681 (2003).
Wang, C. et al., “Transdermal testosterone gel Improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men,”J. Clin. Endocrin.&Metabol., vol. 85, No. 8, pp. 2839-2853 (2000).

Affiliated with

Also associated with

Rating

Penetration enhancing and irritation reducing systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Penetration enhancing and irritation reducing systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Penetration enhancing and irritation reducing systems will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3745186